Creative Medical Technology Holdings, Inc.

CELZ • Biotechnology

$1.11

▲ +0.05 (+4.72%)

Current price

EarningsLatest report: Jun 30, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$4.11M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0Healthy liquidity · 25.97Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:22 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.11

Change4.72%

Shares Out3.70M

Market Cap$4.11M

Enterprise Value$-4.61M

52W Range0.62 - 6.25

Beta1.88

P/E-0.68

P/S1,369.62

P/B0.47

P/FCF-0.70

EV/Sales-1,535.09

Price$1.11

Change4.72%

Shares Out3.70M

Market Cap$4.11M

Enterprise Value$-4.61M

52W Range0.62 - 6.25

Beta1.88

P/E-0.68

P/S1,369.62

P/B0.47

P/FCF-0.70

EV/Sales-1,535.09

EV/EBITDA1.00

EV/FCF0.78

Earnings Yield-147.02%

FCF Yield-143.63%

Dividend Yield0.00%

Gross Margin-19.92%

Oper. Margin-1023.80%

Profit Margin-999.17%

Debt/Eq0.00

Current Ratio25.97

Quick Ratio25.97

Volume665.32K

Avg Volume3.16M

EPS Surprise0.01

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

70/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

70/100

Why this score▼

Manageable debt level · 0Healthy liquidity · 25.97Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

CELZ

Analyst sentiment

Based on 1 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Company Overview

IPO: 11/6/2015

Industry: Biotechnology

P/B i: 0.47

Debt / Equity i: 0.00

Operating Margin: -102380.23%

Net Margin: -99916.80%

ROE i: -

ROIC: -

Financial Health

Score14 / 20

Debt / Equity: 0.00

Current Ratio: 25.97

Quick Ratio: 25.97

Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 2 high-volume insider sells detected

Finger Michael H.

Transaction: 02/19/2025

SELL

Change

-750

Price

$5.75

Filing

02/20/2025

Type

SELL

Finger Michael H.

Transaction: 02/18/2025

SELL

Change

-750

Price

$5.00

Filing

02/20/2025

Type

SELL

Warbington Timothy

Transaction: 06/28/2023

BUY

Change

+200

Price

$4.36

Filing

06/29/2023

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Finger Michael H.	SELL	-750	$5.75	02/19/2025	02/20/2025
Finger Michael H.	SELL	-750	$5.00	02/18/2025	02/20/2025
Warbington Timothy	BUY	+200	$4.36	06/28/2023	06/29/2023
Warbington Timothy	BUY	+300	$4.40	06/27/2023	06/29/2023
Warbington Timothy	BUY	+9,800	$0.39	11/22/2022	11/23/2022
Warbington Timothy	BUY	+10,000	$0.40	11/21/2022	11/23/2022
Finger Michael H.	BUY	+2,000	$0.50	09/27/2022	09/29/2022
Warbington Timothy	BUY	+20,000	$0.50	09/27/2022	09/28/2022
Warbington Timothy	BUY	+12,000	$0.54	09/22/2022	09/22/2022
Warbington Timothy	BUY	+5,000	$0.61	09/21/2022	09/22/2022
Finger Michael H.	BUY	+10,000	$0.70	06/14/2022	06/14/2022
Warbington Timothy	BUY	+2,000	$0.92	06/06/2022	06/07/2022
Finger Michael H.	BUY	+6,500	$1.50	05/20/2022	05/20/2022
Dickerson Donald	BUY	+53,237	$1.69	02/09/2022	02/11/2022
Warbington Timothy	BUY	+58,580	$1.69	02/09/2022	02/11/2022
Snow Susan H	OTHER	0	Not reported	12/02/2021	01/05/2022
Urdang Bruce Steven	OTHER	0	Not reported	12/02/2021	12/13/2021
Finger Michael H.	SELL	0	Not reported	12/02/2021	12/13/2021
Ichim Thomas	SELL	-1,450,000	$0.03	07/22/2021	07/22/2021
Ichim Thomas	SELL	-1,500,000	$0.03	07/21/2021	07/22/2021

About the Company

Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.

Source - link

Peers

ACXP ADIL ADXN ALZN APRE BCDA CDIO HCWB KPRX PHIO

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning

All patients enrolled and treated across original and FDA-cleared expansion cohorts Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising Company remains fully engaged in patient follow-up, data collection, RMAT evaluation and preparation for Phase 3 discussions with FDA for a broader chronic lower back pain population Olastrocel positioned as a potential non-surgical, non-opioid regenerative therapy for a large underserved market PHOENIX, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced that all patients have now been enrolled and treated across the Company's entire FDA-cleared ADAPT clinical trial evaluating CELZ-201 / Olastrocel, including the original study cohorts and the FDA-cleared opioid expansion cohort. CELZ-201, also known as Olastrocel, is the Company's proprietary perinatal tissue-derived, allogeneic regenerative cell therapy candidate being evaluated for chronic lower back pain associated with degenerative disc disease.

GlobeNewsWire

Creative Medical Technology Stock Surges After Key Patent Win

Creative Medical Technology Holdings Inc. (NASDAQ:CELZ) shares are surging Thursday afternoon following an intellectual property milestone.

Benzinga

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

Newly Allowed Patent Protects Cell-Free MyeloCelz™ Exosome Technology Designed to Suppress Autoimmune Destruction of Insulin-Producing Cells, Reinforcing Creative Medical's Multi-Program Diabetes Strategy Newly Allowed Patent Protects Cell-Free MyeloCelz™ Exosome Technology Designed to Suppress Autoimmune Destruction of Insulin-Producing Cells, Reinforcing Creative Medical's Multi-Program Diabetes Strategy

GlobeNewsWire

Creative Medical Technology Holdings Issues Mid-Year Update

Highlights Significant Clinical, Regulatory, and Strategic Progress, Supported by a Disciplined Capital Allocation Strategy Highlights Significant Clinical, Regulatory, and Strategic Progress, Supported by a Disciplined Capital Allocation Strategy

GlobeNewsWire

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds

PHOENIX, June 30, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a biotechnology company dedicated to the advancement of regenerative therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedic, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 2,790,340 shares of common stock of the Company originally issued in October 2025, at a reduced exercise price of $1.60 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-291713). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.5 million, before deducting financial advisory fees. Roth Capital Partners is acting as the Company's financial advisor for this transaction. In consideration for the immediate exercise of the existing warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 5,580,680 shares of common stock, at an exercise price of $1.60 per share upon the receipt of shareholder approval for a term of five years from the initial exercise date. The transaction is expected to close on June 30, 2026. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-08	-0.39	-0.38	0.01
2026-03-20	-0.37	-0.8	-0.43
2025-11-07	-0.48	-0.48	0
2025-08-08	-0.63	-0.48	0.15
2025-05-09	-0.52	-0.83	-0.31
2025-03-14	-0.63	-1.12	-0.49
2024-11-08	-0.85	-0.75	0.1
2024-08-09	-0.84	-1.11	-0.27
2024-05-10	-1.15	-0.73	0.42
2024-03-22	-1.13	-1.21	-0.08
2023-11-14	-0.86	-1.02	-0.16
2023-08-11	-0.83	-0.78	0.05